SLC7A10: A Potential Drug Target for Calcium Signaling and Neurotransmission

Target Name: SLC7A10

NCBI ID: G56301

SLC7A10

SLC7A10: A Potential Drug Target for Calcium Signaling and Neurotransmission

SLC7A10 (Simple Localized Calcium-Transient Activation of Paraldehyde-Responsive Calcium Signaling) is a gene that encodes a protein known as the Paraldehyde-Responsive Calcium Transient Activator (PARCA). The PARCA protein is a key regulator of cellular calcium levels and is involved in a wide range of physiological processes, including muscle contractions, nerve signaling, and cell signaling.

SLC7A10 is a member of the SLC7A family, which includes several other proteins involved in calcium signaling, including SLC7A8 and SLC7A9. These proteins are known as TRPV4 channels and are involved in the regulation of pain perception, neurotransmitter release, and other physiological processes.

The PARCA protein is a Calcium-Transient Activator (CTA), which means that it can be activated by changes in calcium levels. When calcium levels rise, the PARCA protein is activated and works to regulate the movement of calcium ions into the cell. This regulation is important for maintaining proper cellular function, including the control of muscle contractions, nerve signals, and other physiological processes.

SLC7A10 is expressed in many different tissues and cells throughout the body, including muscle cells, nerve fibers, and the brain. It is also involved in several signaling pathways, including the regulation of pain perception and the control of neurotransmitter release.

One of the unique features of SLC7A10 is its ability to activate calcium ions in a rapid and efficient manner. This is important for the rapid switching of cellular signaling pathways, which is critical for maintaining proper cellular function.

SLC7A10 is also involved in the regulation of muscle contractions and is a key regulator of the myosin ATPase, which is responsible for the production of muscle contractions. This suggests that SLC7A10 may be a potential drug target for muscle-related conditions, such as muscle weakness or myopathies.

In addition to its role in muscle contractions, SLC7A10 is also involved in the regulation of neurotransmitter release. This is important for the regulation of mood, anxiety, and other physiological processes. The rapid switching of calcium ions in response to neurotransmitter release is important for the regulation of neurotransmitter release and may be a potential target for the treatment of neurotransmitter-related disorders.

SLC7A10 is also involved in the regulation of pain perception. The rapid switching of calcium ions in response to pain can be a potential target for the treatment of chronic pain.

In conclusion, SLC7A10 is a gene that encodes a protein involved in the regulation of calcium levels and other physiological processes. Its unique ability to activate calcium ions in a rapid and efficient manner makes it a potential drug target for a wide range of conditions, including muscle-related conditions, neurotransmitter-related disorders, and chronic pain. Further research is needed to fully understand the role of SLC7A10 in these processes and to develop effective treatments.

Protein Name: Solute Carrier Family 7 Member 10

Functions: Associates with SLC3A2/4F2hc to form a functional heterodimeric complex that translocates small neutral L- and D-amino acids across the plasma membrane. Preferentially mediates exchange transport, but can also operate via facilitated diffusion (By similarity) (PubMed:10863037). Acts as a major transporter for glycine, L- and D-serine in the central nervous system. At the spinal cord and brainstem regulates glycine metabolism and glycinergic inhibitory neurotransmission by providing for glycine de novo synthesis from L-serine and glycine recycling from astrocytes to glycinergic motor neurons (By similarity). At Schaffer collateral-CA1 synapses mediates D-serine and glycine release that modulates post-synaptic activation of NMDA receptors and excitatory glutamatergic transmission (By similarity). May regulate D-serine release from mesenchymal progenitors located in developing subcutaneous adipose tissue, favoring white adipocyte over thermogenic beige adipocyte lineage commitment (By similarity)

The "SLC7A10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC7A10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets